EUVIMEDEUVIMED entdecken
Open Access

LOXL4, but not LOXL2, is the critical determinant of pathological collagen cross-linking and fibrosis in the lung

Hsiao-Yen Ma iD, Qingling Li, Weng Ruh Wong iD, Elsa-Noah N'Diaye, Patrick Caplazi iD, Hannah Bender iD, Zhiyu Huang, Alexander Arlantico iD, Surinder Jeet, Aaron Wong, Claire Emson iD, Hans Brightbill iD und 5 weitere

Science Advances · 26.05.2023 · 9 (21)

DOI: 10.1126/sciadv.adf0133 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, erschienen am 26.05.2023. Verfasst von Hsiao-Yen Ma und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Discovery Immunology, Genentech, South San Francisco, CA, USA. Hauptthemen laut MEDLINE: Collagen, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Idiopathic pulmonary fibrosis is a progressive fibrotic disease characterized by excessive deposition of (myo)fibroblast produced collagen fibrils in alveolar areas of the lung. Lysyl oxidases (LOXs) have been proposed to be the central enzymes that catalyze the cross-linking of collagen fibers. Here, we report that, while its expression is increased in fibrotic lungs, genetic ablation of LOXL2 only leads to a modest reduction of pathological collagen cross-linking but not fibrosis in the lung. On the other hand, loss of another LOX family member, LOXL4, markedly disrupts pathological collagen cross-linking and fibrosis in the lung. Furthermore, knockout of both Loxl2 and Loxl4 does not offer any additive antifibrotic effects when compared to Loxl4 deletion only, as LOXL4 deficiency decreases the expression of other LOX family members including Loxl2 . On the basis of these results, we propose that LOXL4 is the main LOX activity underlying pathological collagen cross-linking and lung fibrosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CollagenIdiopathic Pulmonary FibrosisHumansLungFibrosisExtracellular MatrixProtein-Lysine 6-Oxidase

Substanzen

CollagenLOXL4 protein, humanProtein-Lysine 6-Oxidase

Autor:innen und Institutionen

  • Department of Discovery Immunology, Genentech, South San Francisco, CA, USA.
  • Department of Microchemistry, Proteomics, and Lipidomics, Genentech, South San Francisco, CA, USA.
  • Department of Pathology, Genentech, South San Francisco, CA, USA.
  • Department of Translational Immunology, Genentech, South San Francisco, CA, USA.
  • Department of Molecular Biology, Genentech, South San Francisco, CA, USA.

ORCID-Profile: Hsiao-Yen Ma, Weng Ruh Wong, Patrick Caplazi, Hannah Bender, Alexander Arlantico, Claire Emson, Hans Brightbill, Lucinda Tam, Merone Roose-Girma, Wendy Sandoval, Ning Ding

Zitieren

APA

Ma, H. Y., Li, Q., Wong, W. R., N'Diaye, E. N., Caplazi, P., Bender, H., Huang, Z., Arlantico, A., Jeet, S., Wong, A., Emson, C., Brightbill, H., Tam, L., Newman, R., Roose-Girma, M., Sandoval, W., & Ding, N. (2023). LOXL4, but not LOXL2, is the critical determinant of pathological collagen cross-linking and fibrosis in the lung. Science Advances, 9(21). https://doi.org/10.1126/sciadv.adf0133

Vancouver

Ma HY, Li Q, Wong WR, N'Diaye EN, Caplazi P, Bender H, et al. LOXL4, but not LOXL2, is the critical determinant of pathological collagen cross-linking and fibrosis in the lung. Science Advances. 2023;9(21). doi:10.1126/sciadv.adf0133

BibTeX
@article{Ma2023,
  author = {Ma, Hsiao-Yen and Li, Qingling and Wong, Weng Ruh and N'Diaye, Elsa-Noah and Caplazi, Patrick and Bender, Hannah and Huang, Zhiyu and Arlantico, Alexander and Jeet, Surinder and Wong, Aaron and Emson, Claire and Brightbill, Hans and Tam, Lucinda and Newman, Robert and Roose-Girma, Merone and Sandoval, Wendy and Ding, Ning},
  title = {LOXL4, but not LOXL2, is the critical determinant of pathological collagen cross-linking and fibrosis in the lung},
  journal = {Science Advances},
  year = {2023},
  volume = {9},
  number = {21},
  doi = {10.1126/sciadv.adf0133}
}
Kostenlos starten →